ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
ASCO 2024 – some Adriatic fears allayed
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Novartis lights up radiopharmaceuticals again
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
